Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Vitamin D Supplementation in Chronic Schizophrenia Patients Treated with Clozapine: A Randomized, Double-Blind, Placebo-controlled Clinical Trial.

Krivoy A, Onn R, Vilner Y, Hochman E, Weizman S, Paz A, Hess S, Sagy R, Kimhi-Nesher S, Kalter E, Friedman T, Friedman Z, Bormant G, Trommer S, Valevski A, Weizman A.

EBioMedicine. 2017 Dec;26:138-145. doi: 10.1016/j.ebiom.2017.11.027. Epub 2017 Dec 2.

2.

Clinical Practice Guidelines for Management of Schizophrenia.

Grover S, Chakrabarti S, Kulhara P, Avasthi A.

Indian J Psychiatry. 2017 Jan;59(Suppl 1):S19-S33. doi: 10.4103/0019-5545.196972. No abstract available.

3.

Using model systems to understand errant plasticity mechanisms in psychiatric disorders.

Averbeck BB, Chafee MV.

Nat Neurosci. 2016 Oct 26;19(11):1418-1425. doi: 10.1038/nn.4413. [Epub ahead of print] Review.

PMID:
27786180
4.

Mortality Rates in Users of Typical and Atypical Antipsychotics: A Database Study in Poland.

Zagozdzon P, Goyke B, Wrotkowska M.

Drugs Real World Outcomes. 2016 Sep;3(3):345-351.

5.

Evaluation of the Safety of Clozapine Use in Patients With Benign Neutropenia.

Richardson CM, Davis EA, Vyas GR, DiPaula BA, McMahon RP, Kelly DL.

J Clin Psychiatry. 2016 Nov;77(11):e1454-e1459. doi: 10.4088/JCP.15m10315.

6.

Weighing the evidence for harm from long-term treatment with antipsychotic medications: A systematic review.

Sohler N, Adams BG, Barnes DM, Cohen GH, Prins SJ, Schwartz S.

Am J Orthopsychiatry. 2016;86(5):477-85. doi: 10.1037/ort0000106. Epub 2015 Dec 14. Review.

7.

Antipsychotic-induced akathisia in delirium: A systematic review.

Forcen FE, Matsoukas K, Alici Y.

Palliat Support Care. 2016 Feb;14(1):77-84. doi: 10.1017/S1478951515000784. Epub 2015 Jun 19. Review.

8.

Health care resource utilization and direct medical costs for patients with schizophrenia initiating treatment with atypical versus typical antipsychotics in Tianjin, China.

He X, Wu J, Jiang Y, Liu L, Ye W, Xue H, Montgomery W.

BMC Health Serv Res. 2015 Apr 9;15:149. doi: 10.1186/s12913-015-0819-y.

9.

Antipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapy.

Fisher MD, Reilly K, Isenberg K, Villa KF.

BMC Psychiatry. 2014 Nov 30;14:341. doi: 10.1186/s12888-014-0341-5.

10.

Role of the axonal initial segment in psychiatric disorders: function, dysfunction, and intervention.

Hsu WC, Nilsson CL, Laezza F.

Front Psychiatry. 2014 Aug 21;5:109. doi: 10.3389/fpsyt.2014.00109. eCollection 2014. Review.

11.

Temporal effects of vascular endothelial growth factor and 3,5-cyclic monophosphate on blood-brain barrier solute permeability in vivo.

Shi L, Zeng M, Fu BM.

J Neurosci Res. 2014 Dec;92(12):1678-89. doi: 10.1002/jnr.23457. Epub 2014 Jul 28.

12.

Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications.

Godman B, Petzold M, Bennett K, Bennie M, Bucsics A, Finlayson AE, Martin A, Persson M, Piessnegger J, Raschi E, Simoens S, Zara C, Barbui C.

BMC Med. 2014 Jun 13;12:98. doi: 10.1186/1741-7015-12-98.

13.

Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study.

Buckley PF, Schooler NR, Goff DC, Hsiao J, Kopelowicz A, Lauriello J, Manschreck T, Mendelowitz AJ, Miller del D, Severe JB, Wilson DR, Ames D, Bustillo J, Mintz J, Kane JM; PROACTIVE Study.

Schizophr Bull. 2015 Mar;41(2):449-59. doi: 10.1093/schbul/sbu067. Epub 2014 May 27.

14.

A drug utilization study of psychotropic drugs prescribed in the psychiatry outpatient department of a tertiary care hospital.

Thakkar KB, Jain MM, Billa G, Joshi A, Khobragade AA.

J Clin Diagn Res. 2013 Dec;7(12):2759-64. doi: 10.7860/JCDR/2013/6760.3885. Epub 2013 Dec 15.

15.

Changes in physician antipsychotic prescribing preferences, 2002-2007.

Donohue J, O'Malley AJ, Horvitz-Lennon M, Taub AL, Berndt ER, Huskamp HA.

Psychiatr Serv. 2014 Mar 1;65(3):315-22. doi: 10.1176/appi.ps.201200536.

16.

Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders.

Macdonald K, Feifel D.

Front Neurosci. 2013 Mar 15;7:35. doi: 10.3389/fnins.2013.00035. eCollection 2013.

17.

Brain connectivity studies in schizophrenia: unravelling the effects of antipsychotics.

Nejad AB, Ebdrup BH, Glenthøj BY, Siebner HR.

Curr Neuropharmacol. 2012 Sep;10(3):219-30. doi: 10.2174/157015912803217305.

18.

Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks.

Menniti FS, Lindsley CW, Conn PJ, Pandit J, Zagouras P, Volkmann RA.

Curr Top Med Chem. 2013;13(1):26-54. Review.

19.

Potential to enhance the prescribing of generic drugs in patients with mental health problems in austria; implications for the future.

Godman B, Bucsics A, Burkhardt T, Piessnegger J, Schmitzer M, Barbui C, Raschi E, Bennie M, Gustafsson LL.

Front Pharmacol. 2013 Jan 7;3:198. doi: 10.3389/fphar.2012.00198. eCollection 2012.

20.

Supplemental Content

Support Center